Peter Marks, the former head of the FDA’s Center for Biologics Evaluation and Research (CBER), has joined Eli Lilly as senior vice president of molecule discovery and head of infectious disease. Marks, who served in his federal role for nearly a decade, previously clashed with Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy. His departure from the FDA occurred amid disagreements with RFK Jr., marking one of the year’s most high-profile exits. In his resignation letter, Marks criticized what he called an “unprecedented assault on scientific truth,” urging an end to practices that hinder medical advancements.
During his tenure, Marks advocated for accelerated approvals of rare disease treatments and played a pivotal role in expediting COVID-19 vaccine development under Operation Warp Speed. However, his career faced scrutiny over decisions such as approving the Alzheimer’s drug Aduhelm and endorsing vaccine boosters despite staff and external adviser concerns. His move to Eli Lilly highlights ongoing debates about the “revolving door” between government agencies and pharmaceutical companies, a pattern also seen with former FDA Commissioner Scott Gottlieb, who joined Pfizer shortly after leaving his federal post.
Marks’ transition underscores tensions over conflicts of interest in regulatory roles, as critics argue such shifts prioritize industry interests over public health. The shift has sparked calls for greater transparency in the relationship between government officials and private sector entities.